Organic Active Ingredients TRIZ Cases

Topical KX-01 dosing treats and helps prevent actinic keratosis while reducing local skin reactions and adverse side effects.

A coated core-particle composition turns self-emulsifying liquids into tablet-ready granules while preserving solubility and absorption stability.

Controlled warm milling and stabilizers keep tegavivint particles below 0.2 microns for stable bioavailable inhalation and parenteral use.

Substituted benzimidazoles inhibit TLR9 while improving selectivity over TLR7/8, stability, and bioavailability for fibrotic disease treatment.

A buffered isotonic furosemide liquid balances pH and concentration to enable stable, less painful subcutaneous self-administration.

A dual preservative and suspending system keeps atomoxetine oral suspension stable, redispersible, palatable, and microbially protected.

Personalized bucindolol dosing by ADRB1 genotype and CYP2D6 status helps reduce atrial fibrillation in heart failure with fewer side effects.

Pressurized heterogeneous aerosolization improves olfactory-region dosing while limiting dripping, swallowing, and systemic side effects.

Low-permeability EP4 agonists concentrate in gastrointestinal and pulmonary tissues to treat disease while limiting cardiovascular side effects.

A glycosylated oleanolic acid compound lowers inflammatory markers and intestinal permeability in ulcerative colitis with Mesalazine-like efficacy.

A buffered high-concentration furosemide liquid balances stability, low injection pain, and self-administered subcutaneous delivery.

Blocking EGFR signaling in TRPV3-linked keratoderma can clear hyperkeratosis, relieve pain, and support sustained remission.

Modified bile acid derivatives resist intestinal BSH and 7α-dehydroxylase, prolong gut activity, and improve fatty liver and glucose metabolism.

A buffered furosemide liquid at pH 6.5-8.5 improves solution stability and enables less painful subcutaneous dosing outside IV settings.

A thickened otic carrier keeps antibacterial, antifungal, and anti-inflammatory agents in the ear canal for days after one application.

Co-administered vector vaccines, cytokines, and checkpoint inhibitors boost memory T-cell formation and sustain anti-cancer immune response.

A flowable chitosan gel reaches hidden jaw hemangioma hemorrhage points, forms local pressure for rapid hemostasis, and helps inhibit bacteria.

Targeted anti-HER2 immunoconjugates combine specific HER2 binding with cytotoxic payloads to inhibit tumor cell proliferation and improve response.

A buffered high-concentration furosemide liquid enables self-administered subcutaneous dosing while balancing stability, efficacy, and injection comfort.

Fluorine-substituted cyclohexene GABA analogues selectively inhibit OAT to curb cancer cell proliferation and tumor growth.

A colored alginate and cross-linker pair makes cartilage application and gel coat formation visible, improving fixation and limiting spread.

Defined free-form and fumaric acid crystal forms improve stability, oral absorbability, and brain penetration for HER2 tumor treatment.

A controlled oral minoxidil formulation extends serum exposure and duration of action for hair loss treatment while reducing rapid-absorption side effects.

Novel pyrazole derivatives act as CFTR correctors and potentiators to address mutation-specific trafficking and gating defects in cystic fibrosis.

Zinc-treated bamboo leaves and nano-impact grinding preserve emerald color, ultrafine particle size, and nutrient stability for food use.

DNA-encoded anti-PcrV and anti-Psl antibodies enable sustained in vivo protection against Pseudomonas infection and biofilm formation.

Selective heterocyclic MCT4 inhibitors reduce cancer cell lactate export while avoiding MCT1 off-target inhibition and improving potency.

Selective side-product formation plus distillation and extraction enables high-purity cannabigerol production without costly chromatography.

By combining a KRAS G12D inhibitor with a dual RAF/MEK inhibitor, this case shows synergistic suppression of tumor cell proliferation and survival.

Benzothiazones are tuned to selectively block Tau-SH3 interactions, helping reduce Aβ-induced neuronal dysfunction and cognitive deficits.

Tailored amino acid formulations exclude serine and glycine to starve tumors while improving efficacy for patient-specific cancer treatment.

pH-responsive ionizable lipids protect nucleic acids yet enable endosomal release, boosting mRNA expression at lower doses with fewer adverse reactions.

Dual IRAK and FLT3 inhibition targets adaptive resistance in AML and MDS while supporting longer response and improved survival.

Formula I compounds broaden KRAS inhibition across wild type and multiple mutations, including resistant cancers beyond G12C-focused drugs.

AR gene testing identifies prostate cancer patients more likely to respond to CYP11A1 inhibitors by blocking upstream steroid biosynthesis.

Heteroaryl derivatives target EGFR and HER2, including C797S-resistant mutants, to suppress kinase activity and cancer cell proliferation.

A pyranochromene eye composition treats degenerative eye disease by protecting mitochondria and reducing injection burden and VEGF-related side effects.

Novel YAP/TEAD modulators constrain Hippo pathway signaling, reduce target gene expression, and offer a route to control tumor growth.

Combining NAD precursors, boosters, and CD38 inhibitors raises NAD+ more effectively by overcoming rate limits and enzymatic degradation.

Bicyclic cGP analogs restore IGF-1 bioavailability and rescue dendritic defects linked to Pitt Hopkins Syndrome symptoms.

Targeting SHP2 offers a monotherapy option for resistant solid tumors, reducing tumor burden and extending progression-free survival.

Azepine-fused compounds target RIPK1 kinase with high selectivity to block pro-inflammatory signaling while limiting off-target kinase effects.

A cyclic amine derivative protects neurons and accelerates myelination to treat diverse peripheral neuropathies with fewer limits than current drugs.

Nitro-functionalized dopamine sutured into gelatin hydrogels improves wet adhesion, conductivity, and cytocompatibility for tissue repair.

Targeting ARNT degradation helps disrupt hypoxic signaling in VHL-mutant cancers, addressing progression and resistance to chemotherapy and radiation.

A ferric meglumine composition removes carbohydrate-related allergy and sugar burdens while enabling parenteral and oral iron use.

Controlled oral minoxidil release maintains therapeutic levels longer while lowering peak serum exposure and adverse effects in hair loss treatment.

Covalent drug-oligonucleotide conjugation improves solubility, cellular uptake, and multi-pathway inflammation regulation without extra carriers.

Specific excipients and particle-size control improve pemafibrate homogeneity and content uniformity, reducing batch-to-batch variation.

Targeted RBM39 degradation with pyrazole-4-sulfonamides modulates splicing and drives selective cancer cell death.